Movement disorders secondary to long-term treatment with cyclosporine A

Arquivos de Neuro-Psiquiatria

Volumn 63, Issue 3 A, 2005, Pages 592-596

  Munhoz, Renato P ^a   Teive, Hello A G ^a,b   Germiniani, Francisco M B ^a   Gerytch Jr , Júlio C ^a   Sá, Daniel S ^a   Bittencourt, Marco A ^a   Pasquini, Ricardo ^a   Camargo, Carlos H F ^a   Werneck, Lineu César ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b NONE   (Brazil)

Author keywords

Bone marrow transplant; Cyclosporine A; Movement disorders; Tremor

Indexed keywords

CYCLOSPORIN A;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; BRADYKINESIA; CHILD; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG USE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NEUROLOGIC EXAMINATION; PARKINSONISM; PREVALENCE; RIGIDITY; TREATMENT OUTCOME; TREMOR;

EID: 24144499152     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-282x2005000400007     Document Type: Article

References (25)

1. Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-1738.
2. Patchell RA. Neurological complications of organ transplantation. Ann Neurol 1994;36:688-703.
3. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997;63:977-983.
4. Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol 1999;246:339-346.
5. Belli LS, De Carlis L, Romani F, et al. Dysarthria and cerebellar ataxia: late occurrence of severe neurotoxicity in a liver transplant recipient. Transpl Int 1993;6:176-178.
6. Kim HC, Han SY, Park SB, Suh SJ. Parkinsonism during cyclosporine treatment in renal transplantation. Nephrol Dial Transplant 2002;17: 319-321.
7. Wasserstein PH, Honig LS. Parkinsonism during cyclosporine treatment. Bone Marrow Transplant 1996;18:649-650.
8. Wijdicks EF, Wiesner RH, Krom RA. Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression. Neurology 1995;45:1962-1964.
9. Combarros O, Fabrega E, Polo JM, Berciano J. Cyclosporine-induced chorea after liver transplantation for Wilson's disease. Ann Neurol 1993;33:108-109.
10. Bain PG, Findley LJ, Atchison P, et al. Assessing tremor severity. J Neurol Neurosurg Psychiatry 1993;56:868-873.
11. Fahn S, Elton RL, and members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, (eds). Recent developments in Parkinson's disease. New York: MacMillan, 1987:153-163.
12. O'Sullivan DP. Convulsions associated with cyclosporin A. Br Med J 1985; 290: 858.
13. Trocha K, Winkler M, Haas J, Ringe B, Wurster U, Ehrenheim C. Neurological examinations after liver transplantation concerning patients under corticosteroid immunosuppression and either FK 506 or cyclosporin. Transpl Int 1994;7(Suppl)1:S43-S49.
14. Menegaux F, Keeffe EB, Andrews BT, et al. Neurological complications of liver transplantation in adult versus pediatric patients. Transplantation 1994;58:447-450.
15. Vazquez de Prada JA, Martin-Duran R, Garcia-Monco C, et al. Cyclosporine neurotoxicity in heart transplantation. J Heart Transplant 1990;9:581-583.
16. Zétola VHF, Scola RH, Pasquini R, Werneck LC. Investigaç ão de neuropatia periférica durante o período recente do transplante de medula óssea. Arq Neuropsiquiatr 1998;56:267-273
17. Atkinson K, Biggs J, Darveniza P, Boland J, Concannon A, Dodds A. Spinal cord and cerebellar-like syndromes associated with the use of cyclosporine in human recipients of allogeneic marrow transplants. Transplant Proc 1985;17:1673-1675.
18. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 2000;13:313-326.
19. Schumacher JM, Ellias SA, Palmer EP, et al. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 2000;54:1042-1050.
20. Hauser RA, Freeman TB, Snow BJ, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 1999;56:179-187.
21. Borlongan CV, Freeman TB, Hauser RA, Cahill DW, Sanberg PR. Cyclosporine-A increases locomotor activity in rats with 6-hydroxydopamine- induced hemiparkinsonism: relevance to neural transplantation. Surg Neurol 1996;46:384-388.
22. Fienberg AA, Hiroi N, Mermelstein PC, et al. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 1998;281: 838-842.
23. Meyer MA. Elevated basal ganglia glucose metabolism in cyclosporine neurotoxicity: a positron emission tomography imaging study. J Neuroimaging 2002;12:92-93.
24. Borlongan CV, Stahl CE, Fujisaki T, Sanberg PR, Watanabe S. Cyclosporine A-induced hyperactivity in rats: is it mediated by immunosuppression, neurotrophism, or both? Cell Transplant 1999;8:153-159.
25. Tsujikawa K, Dan Y, Nogawa K, et al. Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A. Biopharm Drug Dispos 2003;24:105-114.